Tag Archive for: Medtech

Amber Implants Secures FDA 510(k) Clearance for VCFix® Spinal System: A Next-Generation Solution for Vertebral Compression Fractures

/in

FDA clearance confirms robust safety and performance of VCFix® Spinal System, a breakthrough treatment for vertebral compression fractures US commercial pilot launch planned for early 2026, followed by broader physician availability from summer 2026 One-year trial data show significant clinical improvements, supporting VCFix® Spinal System as a potential new standard of care The Hague, The […]

Read more

ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump

/in

Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT Life Sciences and Health Innovations, demonstrating strong confidence in ViCentra’s next phase of growth Fresh capital fuels scale-up, regulatory pathway, and commercialization of Kaleido 2, the world’s smallest, lightest, and […]

Read more

Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial

/in

Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency  In an earlier, separate trial, Xabg recently demonstrated patency with excellent flow in a 24-month trial – the first time ever this duration has been achieved Supports potential of Xabg to transform CABG surgery landscape and eliminate need for […]

Read more

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

/in

Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused […]

Read more